Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sierra, C.
Right arrow Articles by Ruilope, L. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sierra, C.
Right arrow Articles by Ruilope, L. M
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*High Blood Pressure
Hazardous Substances DB
*SPIRONOLACTONE
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Reviews

Review: Role of the selective aldosterone receptor blockers in arterial hypertension

Cristina Sierra

Hypertension Unit, Hospital Clinic, Barcelona, Spain

Luis M Ruilope

Hypertension Unit, Hospital Doce de Octubre, Madrid, Spain, Luis_M_Ruilope{at}teleline.es

Aldosterone can cause cardiovascular injury in animals and men. The aldosterone blocker, spironolactone, has been shown to reduce mortality in patients with congestive heart failure. The use of this drug in arterial hypertension has been limited by the high frequency of adverse effects. Recently published data with a new aldosterone blocker, eplerenone, have confirmed the benefits of aldosterone blockade in patients post-myocardial infarction, as well as in the regression of left ventricular hypertrophy in hypertensive patients and of microalbuminuria in Type 2 diabetic patients. The fact that eplerenone is much better tolerated open the possibility of this therapy in cardiovascular, as well as in renal disease.

Key Words: aldosterone blockers • spironolactone • eplerenone • arterial hypertension • target organ damage

Journal of Renin-Angiotensin-Aldosterone System, Vol. 5, No. 1, 23-25 (2004)
DOI: 10.3317/jraas.2004.002
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement